Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 13/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.42 |
| ▸ | GAA | P10253 | 8/20 | 0.42 |
| ▸ | HPGD | P15428 | 8/20 | 0.42 |
| ▸ | GLA | P06280 | 7/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 5/20 | 0.39 |
| ▸ | CASP7 | P55210 | 5/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1904410 | 0.85 | KDM4E (0.42) | L3MBTL1KDM4EALDH1A1GAAHPGD | |
| SCHEMBL12262393 | 0.84 | L3MBTL1 (0.47) | L3MBTL1KDM4EALDH1A1GAAHPGD | |
| SCHEMBL11986412 | 0.83 | L3MBTL1 (0.46) | L3MBTL1KDM4EALDH1A1GAAHPGD | |
| SCHEMBL1897638 | 0.82 | PIK3CA (0.55) | L3MBTL1KDM4EALDH1A1GAAHPGD | |
| SCHEMBL1899094 | 0.81 | KDM4E (0.63) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL15580732 | 0.81 | KDM4E (0.44) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL1899875 | 0.73 | ADORA2A (0.41) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL1901964 | 0.72 | PIK3CA (0.73) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL1905815 | 0.72 | PIK3CA (0.47) | KDM4EALDH1A1GAAHPGDGLA | |
| SCHEMBL20614333 | 0.71 | HSD17B10 (0.39) | KDM4EALDH1A1GAAHPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322523-B1 | Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS INC (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-2322523-B1 | Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS INC (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-2139484-B9 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2139484-B9 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8513266-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | EXELIXIS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513266-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | EXELIXIS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513266-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | EXELIXIS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-1940839-B1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kalpha | EXELIXIS INC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2139484-B1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2142543-B1 | PYRIDO [2, 3-D]PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2010-06-17 | — | — | US | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | EXELIXIS, INC (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2008127678-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF PI3K-ALPHA FOR THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008124161-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2007044813-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062274-A1 | Pyridopyrimidinone inhibitors of pi3kalpha | PIK3CA, PIK3CD, PIK3CB | L3MBTL1 4451/4885KDM4E 2571/4885ALDH1A1 1878/4885 |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | PLK3, PLK4, PLK2 | L3MBTL1 953/4885KDM4E 1016/4885ALDH1A1 1153/4885 |
| US-20100150827-A1 | PYRIDO [2, 3-D] PYRIMIDIN-7-ONE COMPOUNDS AS INHIBITORS OF P13K-ALPHA FOR THE TREATMENT OF CANCER | PIK3CA, CDKN1A, PIK3CD | L3MBTL1 2553/4885KDM4E 865/4885ALDH1A1 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.